The popular obesity drug ‘Wegovy’ appears to improve body mass index in children with obesity. Getty Images Bank

The popular obesity drug ‘Wegovy’ appears to improve body mass index in children with obesity. Provided by Getty Images Bank

Evidence now shows that the obesity treatment Wegovy (ingredient name: semaglutide) is effective even in children under 12. After 68 weeks of treatment, 4 out of 10 participants no longer met the criteria for obesity. 

 

On the 7th (local time), Danish pharmaceutical company Novo Nordisk announced preliminary results from a phase 3 clinical trial conducted in 165 children with obesity aged 6 or older but younger than 12. 

 

Although the number of children with obesity is rising, treatment options remain limited. Children with obesity are known to face a higher risk of cardiovascular disease, along with challenges such as depression, eating disorders, and even bullying. Without effective interventions, pediatric obesity can progress into adult obesity, leading to more serious complications and a potential reduction in life expectancy. 

  

More than 85% of the children who took part in this trial had class II obesity, defined as a body mass index (BMI) of 35 or higher by adult standards, or class III obesity, defined as a BMI of 40 or higher. Class II and III obesity correspond to severe obesity.  

 

Participants were randomly assigned to receive a once-weekly injection of semaglutide or a placebo (dummy drug). Semaglutide was administered at doses up to 1.7 mg or 2.4 mg. During treatment, they also followed lifestyle interventions such as a low-calorie diet and increased physical activity. 

 

Over the 68-week trial period, children in the semaglutide group showed a statistically significant reduction in BMI compared with the placebo group. In the Wegovy group, 40.4% of participants fell below the obesity threshold and improved to overweight or normal weight. In contrast, not a single child in the placebo group moved out of the obesity category. 

 

The safety and tolerability profile of semaglutide was consistent with what has been observed in previous trials involving adults and adolescents. No side effects or warning signals related to physical growth or pubertal development were reported. 

 

Ania M. Jastreboff, a professor of pediatrics at Yale School of Medicine in the United States, said in a Novo Nordisk press release, “Pediatric obesity is concerning because it increases the likelihood of progressing to adult obesity or developing obesity-related complications at an early age,” adding, “We are encouraged to see that semaglutide treatment brought 40% of children below the obesity threshold.” 

 

Martin Holst Lange, executive vice president and chief scientific officer (CSO) at Novo Nordisk, said, “We have confirmed that semaglutide has the potential to provide tangible help to children with obesity who require medical treatment,” and added, “It may help prevent serious health risks that would otherwise emerge in adulthood.” 

 

Detailed clinical data from this trial are scheduled to be officially presented at the “Obesity Society 2026” annual scientific meeting, to be held in Washington, D.C., USA, from November 14 to 17. 

Copyright ⓒ DongA Science. All rights reserved.